上皮性卵巢癌患者DNA聚合酶η蛋白表达差异与TP方案临床疗效关系研究  

Correlative analysis on the expression of DNA polymeraseηprotein and clinical efficacy of paclitaxel and cisplatin strategy on patients with epithelial ovarian cancer

作　　者：曾勇[1] 曹丽芝[1] 任华益[1] 陈金燕[1] 

机构地区：[1]湖南省肿瘤医院药学部,湖南长沙410013

出　　处：《肿瘤药学》2011年第1期54-56,共3页Anti-Tumor Pharmacy

摘　　要：目的观察上皮性卵巢癌患者DNA聚合酶η蛋白的表达差异与TP方案化疗临床疗效的关系。方法选取我院住院治疗的上皮性卵巢癌患者50例,所有患者均卵巢癌肿瘤细胞减灭术后采用TP方案进行一线化疗。采用免疫组化法检测癌组织中的DNA聚合酶η蛋白表达,分析治疗效果与DNA聚合酶η蛋白表达之间的关系。结果目的蛋白表达差异与近期疗效有关,聚合酶表达强阳性组有效率为46.2%,阳性组有效率为60.0%,阴性组有效率为83.3%。三组比较差异有显著性(P<0.05)。DNA聚合η蛋白表达强阳性组中位生存时间为15.7±3.6个月,阳性组18.5±2.7个月,阴性组28.3±1.9个月。3组间比较,差异有显著性(P<0.05)。结论 DNA聚合η蛋白表达量与TP方案化疗的近。Objective To explore the relationship between the DNA polymerase expression vari- ation and clinical efficacy in patients with epithelial ovarian cancer treated by paclitaxel and cisplatin. Method 50 patients with epithelial ovarian cancer were selected and treated by paclitaxel and cisplatin. The expression of DNA polymerase η protein was evaluated by immunohistochemistry. The relationship between expression of DNA polymerase η protein and clinical efficacy were analyzed. Results The response rates of strong positive expression group, positive group and negative group were 46.2%, 60.0%, 83.3% respectively. The difference was significant. The median survival time of three groups was 15.7 ± 3.6 months, 18.5 ± 2.7 months, 28.3±1.9 months. The difference was significant （P〈0.05）. Conclusion The expression of DNA polymerase rI silencing was correlative to the clinical efficacy of paclitaxel and cisDlatin.

关 键 词：上皮性卵巢癌 DNA聚合酶η蛋白 临床疗效 

分 类 号：R737.31[医药卫生—肿瘤] R730.53[医药卫生—临床医学]